| 姓名 | 職稱 | 持有股份 | 代表法人 |
|---|---|---|---|
| Zhou,Guo-Zhong | Chairman | 12.54% | GUO XUAN INVESTMENT CO., LTD. |
| Chen,Hong-Ren | Director | 0.67% | |
| Wang,Jie | Director | 0.26% | |
| She,Zhong-Cai | Director | 0.35% | |
| Liu,Sun-De | Director | 8.77% | MENG TE KE INVESTMENT CO., LTD. |
| Qian,Shi-Zhong | Director | 0.38% | |
| Gong,Jun-Ji | Independent Director | 0.00% | |
| You,Zhong-Ying | Independent Director | 0.00% | |
| Lin,Fen-Hui | Independent Director | 0.00% | |
| Chen,Mei-Qin | Independent Director | 0.00% |
Change Company Name to WeLeader Biomedical Co. , Ltd.
2024/07/18
Change Company Name to WELLIDE BIOMEDICAL CO., LTD. (FORMER NAME: WELLIDE CO., LTD.)
2022/07/27
Change Capital to 800,000,000
2022/07/15
Change Capital to 300,000,000
2021/07/16
Change Capital to 250,000,000
2018/07/11
Change Capital to 120,000,000
2015/09/23
Change Capital to 80,000,000
2014/11/19
Change Capital to 50,000,000
2013/03/27
Change Capital to 35,000,000
2011/11/21
Change Company Name to WeLeader Biomedical Co. , Ltd.
2011/11/01
Change Person in Charge to Zhou,Guo-Zhong
2011/11/01
下載完整報告查看完整數據
| 項目 | 2025 | 2024 | 2023 |
|---|---|---|---|
| Operating income | 245,133 | 991,125 | 940,698 |
| Operating cost | 167,140 | 674,801 | 642,620 |
| Profit (loss) of initial recognition of biological asset and agricultural products | - | - | - |
| Profit (loss) on changes in fair value less costs to sell of biological asset for current period | - | - | - |
| Operating gross profit (loss) | 77,993 | 316,324 | 298,078 |
| Unrealized profit (loss) on sales of goods | - | - | - |
| Realized profit (loss) on sales of goods | - | - | - |
| Operating gross profit (loss), net | 77,993 | 316,324 | 298,078 |
| Operating expenses | 27,648 | 102,187 | 100,115 |
| Other gain (loss), net | - | - | - |
| Operating profit (loss) | 50,345 | 214,137 | 197,963 |
| Non-operating income and expenses | 877 | 1,069 | -4,418 |
| Net profit (loss) before tax | 51,222 | 215,206 | 193,545 |
| Income tax expense (benefits) | 10,244 | 44,994 | 41,262 |
| Net profit (loss) of ongoing business for the current period | 40,978 | 170,212 | 152,283 |
| Profit (loss) of closed units | - | - | - |
| Profit (loss) of non-jointly controlled equity before merger | - | - | - |
| Net profit (loss) for the current period | 40,978 | 170,212 | 152,283 |
| Other comprehensive profit (loss), net | - | -11,893 | 15,291 |
| Comprehensive net profit and loss of non-jointly controlled equity before merger | - | - | - |
| Total comprehensive profit and loss for the current period | 40,978 | 158,319 | 167,574 |
| Net profit (loss) attributable to owners of parent company | 40,978 | 170,212 | 152,283 |
| Net profit (loss) form equity attributable to former owner of business combination under common control | - | - | - |
| Net profit (loss) attributable to non-controlling interests | - | - | - |
| Comprehensive profit (loss) attributable to owners of parent company | 40,978 | 158,319 | 167,574 |
| Comprehensive profit (loss) form equity attributable to former owner of business combination under common control | - | - | - |
| Comprehensive profit (loss) attributable to non-controlling interests | - | - | - |
| Basic earnings per share (yuan) | 0 | 4 | 3 |
| 項目 | 2025 | 2024 | 2023 |
|---|---|---|---|
| Net cash inflow (outflow) from operating activities | 71,979 | 278,764 | 231,864 |
| Net cash inflows (outflows) from investing activities | -81,043 | -196,654 | -113,956 |
| Net cash inflow (outflow) from financing activities | 130,927 | -1,831 | -123,941 |
| Effect of Exchange Rate Changes on Cash and Cash Equivalents | - | - | - |
| Increase (decrease) in cash and cash equivalents in the current period | 121,863 | 80,279 | -6,033 |
| Beginning balance of cash and cash equivalents | 174,972 | 94,693 | 100,726 |
| Ending balance of cash and cash equivalents | 296,835 | 174,972 | 94,693 |
| 項目 | 2025 | 2024 | 2023 |
|---|---|---|---|
| Current asset | 760,474 | 591,319 | 450,420 |
| Non-current asset | 1,434,562 | 1,406,743 | 1,277,140 |
| Total asset | 2,195,036 | 1,998,062 | 1,727,560 |
| Current liability | 554,861 | 469,005 | 401,689 |
| Non-current liability | 604,090 | 620,590 | 480,092 |
| Total liability | 1,158,951 | 1,089,595 | 881,781 |
| share capital | 454,789 | 415,789 | 415,789 |
| Equity - secruity token | - | - | - |
| capital reserve | 341,944 | 141,131 | 141,131 |
| retained earning | 238,960 | 351,155 | 276,574 |
| Other equity | 392 | 392 | 12,285 |
| Treasury stock | - | - | - |
| Total equity attributable to owners of parent company | 1,036,085 | 908,467 | 845,779 |
| Equity attributable to former owner of business combination under common control | - | - | - |
| Equity attributable to non-controlling interest before business merger under common control | - | - | - |
| Non-controlling interests | - | - | - |
| Total Equity | 1,036,085 | 908,467 | 845,779 |
| Share capital awaiting retirement (unit: share) | - | - | - |
| Issued shares of advance equity (unit: shares) | 0 | 0 | 0 |
| Treasury shares of the parent company held by the parent company and its subsidiaries (unit: share) | 0 | 0 | 0 |
| Net asset value per share | 22 | 21 | 20 |
